The YCC Administration provides infrastructure to promote cancer research activities of its 260 members, with a particular emphasis on facilitating transdisciplinary and translational research. The Administration supports the Director, Senior Leaders, Program Leaders, Shared Resources Directors and YCC Members in carrying out the YCC mission through effective management, centralized resources, and strategic planning. YCC Administrative responsibilities: ? Communicate between and among Center Director, Deputy, Associate and Assistant Directors,, Program Leaders, Shared Resource Directors and stakeholders within and outside the Institution; ? Develop and implement the YCC strategic plan in concert with the Center's leadership and integrate recommendations from standing and ad hoc advisory boards; ? Develop and coordinate research administration activities to support planning and evaluation, integrate and promote the collaborative, transdisciplinary and translational research activities of the YCC; ? Provide financial management of all YCC and CCSG funds and accounts;maintain fiduciary responsibility including preparing and maintaining annual operating,, capital and Shared Resource budgets;intra- and extramural research fund management;tracking Shared Resource usage;preparing grants, contracts and other financial reports; * Provide personnel and human resource services in support of YCC leadership and membership; * Manage Shared-Resources and provide financial oversight, data on usage patterns, and determine chargeback rate; * Manage YCC facilities, space, and equipment; * Manage and coordinate funding opportunities including intramural pilot project programs and other research project post award management; * Support and coordinate YCC membership application and review processes; * Manage and respond to research information technology and informatics needs; * Coordinate YCC committees;management of human resources, development, marketing, public affairs, and education programs.
The administration is a key component of the YCC. A highly effective administration is of paramount importance for the YCC and its members to achieve their missions. The administration's chief priority is to ensure the effective execution of business, administrative, and financial operations such that the research activities of YCC members can flourish.
|Wimberly, Hallie; Brown, Jason R; Schalper, Kurt et al. (2015) PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunol Res 3:326-32|
|Ma, Xiaomei; Wang, Rong; Long, Jessica B et al. (2014) The cost implications of prostate cancer screening in the Medicare population. Cancer 120:96-102|
|Herbst, Roy S; Soria, Jean-Charles; Kowanetz, Marcin et al. (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563-7|
|Durazzo, Tyler S; Tigelaar, Robert E; Filler, Renata et al. (2014) Induction of monocyte-to-dendritic cell maturation by extracorporeal photochemotherapy: initiation via direct platelet signaling. Transfus Apher Sci 50:370-8|
|Black, Jonathan D; English, Diana P; Roque, Dana M et al. (2014) Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer. Womens Health (Lond Engl) 10:45-57|
|Smith, Matthew R; Halabi, Susan; Ryan, Charles J et al. (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143-50|
|Cao, Jian; Liu, Zongzhi; Cheung, William K C et al. (2014) Histone demethylase RBP2 is critical for breast cancer progression and metastasis. Cell Rep 6:868-77|
|Gonzalez, A L; Berger, C L; Remington, J et al. (2014) Integrin-driven monocyte to dendritic cell conversion in modified extracorporeal photochemotherapy. Clin Exp Immunol 175:449-57|
|O'Malley, Stephanie S; Wu, Ran; Mayne, Susan T et al. (2014) Smoking cessation is followed by increases in serum bilirubin, an endogenous antioxidant associated with lower risk of lung cancer and cardiovascular disease. Nicotine Tob Res 16:1145-9|
|Chen, Lieping (2014) From the guest editor: Tumor site immune modulation therapy. Cancer J 20:254-5|
Showing the most recent 10 out of 72 publications